Meeting
2012 ASCO Annual Meeting
Vinorelbine plus cisplatin versus gefitinib in resected non-small cell lung cancer haboring activating EGFR mutation (WJOG6410L).
Authors
Hirohito Tada
Department of General Thoracic Surgery, Osaka City General Hospital, Osaka, Japan
Hirohito Tada , Koji Takeda , Kazuhiko Nakagawa , Isamu Okamoto , Tetsuya Mitsudomi , Yukito Ichinose , Kenji Sugio , Masahiro Tsuboi , Yoichi Nakanishi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
UMIN000006252
Citation
J Clin Oncol 30, 2012 (suppl; abstr TPS7110)
DOI
10.1200/jco.2012.30.15_suppl.tps7110
Abstract #
TPS7110
Poster Bd #
43E
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Updated overall survival (OS) and exploratory analysis from the randomized, phase II EVAN study of erlotinib (E) versus vinorelbine plus cisplatin (NP) as adjuvant therapy in Chinese patients with stage IIIA EGFR+ NSCLC.
First Author: Dongsheng Yue
Poster
2015 ASCO Annual Meeting
Common and rare EGFR mutations (EGFRm) in the RADIANT trial: Final follow-up with 5 year data.
First Author: Frances A. Shepherd
Poster
2014 ASCO Annual Meeting
A meta-analysis of smoking status on clinical outcomes of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor.
First Author: Yoshikazu Hasegawa
Poster
2011 ASCO Annual Meeting
The SELECT trial: A multicenter phase II trial of adjuvant erlotinib (E) in patients with resected, early-stage non-small cell lung cancer (NSCLC) and confirmed mutations in the epidermal growth factor receptor (EGFR).
First Author: N. A. Pennell